AAP
DAWN

Arax Advisory Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Arax Advisory Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.92K Buy
323
+311
+2,592% +$4.38K ﹤0.01% 2639
2025
Q4 		$112 Sell
12
-1,021
-99% -$8.53K ﹤0.01% 3807
2025
Q3 		$7.28K Buy
+1,033
New +$7.11K ﹤0.01% 2731
2024
Q4 		– Sell
-8
Closed -$112 – 2502
2024
Q3 		$112 Hold
8
– – ﹤0.01% 2553
2024
Q2 		$111 Buy
+8
New +$117 ﹤0.01% 2486

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arax Advisory Partners's DAWN Position: Q1 2026 in Review

Arax Advisory Partners increased its Day One Biopharmaceuticals (DAWN) stake by 2,592% in Q1 2026, buying an estimated $4.38K and bringing the position to 323 shares worth $6.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

Arax Advisory Partners first reported a position in DAWN in Q2 2024 and has held it in 5 quarters since. The position peaked at $7.28K in Q3 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Arax Advisory Partners held 323 shares of Day One Biopharmaceuticals worth $6.92K as of Q1 2026.
  • Arax Advisory Partners bought 311 Day One Biopharmaceuticals shares in Q1 2026, an estimated $4.38K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2639 holding.
  • Arax Advisory Partners first reported a position in Day One Biopharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Day One Biopharmaceuticals position peaked at $7.28K in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.